Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children

A Wrotek1, T Jackowska, K Pawlik

  • 1Department of Pediatrics, Medical Center of Postgraduate Education, 99/103 Marymoncka St., Warsaw, 01-813, Poland.

Insights

Soluble urokinase plasminogen activator receptor (suPAR) levels are higher in children with pneumonia, indicating potential as a biomarker for disease severity and immune system activation.

Area of Science:

  • Pediatrics
  • Immunology
  • Biomarkers

Background:

  • Soluble urokinase plasminogen activator receptor (suPAR) is linked to immune system activation.
  • Limited data exist on suPAR as a biomarker for pneumonia severity.

Purpose of the Study:

  • To determine suPAR levels in hospitalized children with community-acquired pneumonia (CAP).
  • To correlate suPAR levels with CAP severity.
  • To compare suPAR levels between children with and without pneumonia.

Main Methods:

  • Study included 596 children (447 with pneumonia, 119 healthy).
  • suPAR levels measured in pneumonia patients and healthy controls.
  • CAP severity assessed using clinical and laboratory indicators.

Main Results:

  • Children with pneumonia had significantly higher suPAR levels (median 7.11 ng/mL) than healthy children (4.68 ng/mL).
  • suPAR correlated positively with fever, time to defervescence, hospital stay, CRP, and procalcitonin.
  • suPAR levels were higher in severe CAP cases.
  • suPAR correlated inversely with sodium and saturation.

Conclusions:

  • Elevated suPAR levels are observed in pediatric pneumonia.
  • suPAR may serve as a valuable biomarker reflecting pneumonia severity in children.

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.3K
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
17
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
73
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K